Replies to post #925 on Radient Pharmaceuticals Corporation fka RXPC

[glasssoto]

BOOYA Radient Pharmaceuticals Receives NYSE Amex Approval for Debt to
Equity Exchange


TUSTIN, CA -- (MARKETWIRE) -- 01/07/11 --

Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based company
specializing in the research, development, and international commercialization
of In Vitro Diagnostic cancer tests, announced today it has received approval
from the New York Stock Exchange AMEX to issue RPC common stock pursuant to
proposals approved by RPC's shareholders on December 3, 2010
(http://www.radient-pharma.com/pdf/press_releases/2010/120610%20ASM_Voting%20Res
ults.pdf).

According to RPC Chairman and CEO Douglas MacLellan, "We are pleased with the
NYSE Amex approval and believe this sets the Company and on a solid path for
the future growth and financial stability. Based upon shareholder and NYSE Amex
approval of the various note transactions, warrant conversions and debt
exchange agreements, RPC is in a position to have up to approximately $27
million in debt and $14 million in other liabilities eliminated. As a result,
we anticipate an increase of approximately $41 million in total shareholder's
equity."